| With DM (n = 107) | Without DM (n = 107) | RR (95% CI) or p-valuea | ||
Antenatal ASB | |||||
GA at first urine result (weeks) | 11.4 ± 4.2 | 11.3 ± 4.5 | 0.609 | ||
AB use < 2 weeks for “ASB screening” | 2 | 1.9% | 2 | 1.9% | - |
Results first urine culture “ASB screening” § ASB without GBS § GBS ASB § Culture-confirmed UTI § No significant growth |
2 4 1 100 |
1.9% 3.7% 0.9% 93.5% |
2 2 4 99 |
1.9% 1.9% 3.7% 92.5% |
0.5260
|
Total ASB including GBS first culture | 6 | 5.6% | 4 | 3.7% | 1.50 (0.44 - 5.17) |
Antenatal UTI | |||||
Clinical UTI | 5 | 4.7% | 12 | 11.2% | 0.42 (0.15 - 1.14) |
Culture-confirmed UTI | 3 | 2.8% | 4 | 3.7% | 0.75 (0.17 - 3.27) |
Received AB treatment for clinical UTI | 5 | 4.7% | 11 | 10.3% | 0.46 (0.16 - 1.26) |
Admission for UTI (pyelonephritis) | 1 | 0.9% | 1 | 0.9% | 1.00 (0.06 - 15.78) |
ASB associated with development of clinical UTI (n = 10) | 0 | - | 0 | - | - |
Post-partum | |||||
Clinical UTI | 3 | 2.8% | 1 | 0.9% | 3.00 (0.32 - 28.39) |
Culture-confirmed UTI | 1 | 0.9% | 1 | 0.9% | 1.00 (0.06 - 15.78) |
Admission for UTI (pyelonephritis) | 0 | - | 1 | 0.9% | - |